id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-2880-0007,FDA,FDA-2016-N-2880,"Microbiology Devices; Reclassification of Cytomegalovirus Deoxyribonucleic Acid Quantitative Assay Devices
Intended for Transplant Patient Management",Rule,Final Rule,2024-09-23T04:00:00Z,2024,9,2024-09-23T04:00:00Z,,2024-09-23T14:03:50Z,2024-21616,0,0,090000648676a027
FDA-2016-N-2880-0004,FDA,FDA-2016-N-2880,"Microbiology Devices; Reclassification of Cytomegalovirus Doxyribonucleic Acid Quantitative Assay Devices Intended for Transplant Patient Management, To Be Renamed Quantitative Cytomegalovirus Nucleic Acid Tests for Transplant Patient Management",Proposed Rule,Request for Comment,2020-09-18T04:00:00Z,2020,9,2020-09-18T04:00:00Z,2020-11-18T04:59:59Z,2020-11-18T02:01:34Z,2020-20716,0,0,090000648486493f
FDA-2016-N-2880-0001,FDA,FDA-2016-N-2880,"Microbiology Devices Panel of the Medical Devices Advisory Committee;
Notice of Meeting; Establishment of a Public Docket; Request for Comments",Notice,Request for Comments,2016-10-04T04:00:00Z,2016,10,2016-10-04T04:00:00Z,2016-12-02T04:59:59Z,2016-12-02T02:01:47Z,2016-23895,0,0,09000064822912e3